ICON Public Company (ICLR) Q4 2023 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2023 earnings summary
15 Oct, 2026Executive summary
FY23 revenue rose 4.9% to $8,120.2m; adjusted EBITDA increased 14.5% to $1,694.1m at a 20.9% margin, and adjusted diluted EPS rose 8.9% to $12.79.
Q4 revenue was $2,066.2m, up 5.3% reported; adjusted EBITDA was $448.2m at a 21.7% margin, and adjusted diluted EPS was $3.46, up 10.5%.
FY net business wins were $9,946m, book-to-bill was 1.22, and closing backlog reached $22.8bn, up 10.0% YoY.
Financial highlights
FY GAAP net income was $612.3m ($7.40 diluted EPS), versus adjusted net income of $1,058.2m ($12.79 adjusted diluted EPS).
Q4 GAAP net income was $216.4m ($2.60 diluted EPS), versus adjusted net income of $287.5m ($3.46 adjusted diluted EPS).
Revenue grew 4.9% reported and 4.6% at constant currency for FY23; Q4 growth was 5.3% reported and 4.1% at constant currency.
Adjusted net income effective tax rate was 15.2% in Q4 and 15.5% for FY23.
Outlook and guidance
FY24 revenue guidance is $8.4bn–$8.8bn, growth of 3.4%–8.4%; adjusted diluted EPS guidance is $14.50–$15.30, growth of 13.4%–19.6%.
Guidance assumes ~50 bps adjusted EBITDA margin expansion, ~$1.1bn free cash flow, $200m–$230m interest expense, and $150m–$200m capital expenditure.
FY24 guidance assumes a 16.5% effective tax rate; adjusted EPS guidance is non-GAAP and excludes share repurchases and additional M&A.
Latest events from ICON Public Company
- Record $3.15B net wins; FY26 revenue guidance rose to $8.1B–$8.2B.ICLR
Q3 2026 - Q2 2026 saw $2,063.5m revenue, 15.9% EBITDA margin, and strong bookings amid margin pressure.ICLR
Q2 2026 - Leadership transition and strategic focus on biotech, automation, and growth drive optimism.ICLR
Baird Global Healthcare Conference 2025 - Global regulators are advancing frameworks to include pregnant individuals in clinical trials.ICLR
Status Update - Q1 2026 revenue rose 0.9% to $2,034m, with strong bookings and reaffirmed guidance.ICLR
Q1 2026 - 2025 revenue and EPS fell after restatements; 2026 targets margin recovery and growth.ICLR
Q4 2025 - Q2 2024 saw strong growth, higher EPS, record backlog, and upgraded full-year guidance.ICLR
Q2 2024 - Growth targets of 7%-10% hinge on innovation, automation, and expanded pharma partnerships.ICLR
Jefferies 2024 Global Healthcare Conference - Revenue fell 4.3% in Q1 2025 as cancellations and COVID trial removals pressured outlook.ICLR
Q1 2025